Kan Chen
Directeur/Membre du Conseil chez CONNECT BIOPHARMA HOLDINGS LIMITED
Profil
Kan Chen is currently a Director at CANbridge Life Sciences Ltd., Suzhou Connect Biopharma Co. Ltd., InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc., InSilico Medicine Cayman TopCo, Connect Biopharma Holdings Ltd., Zion Pharma Ltd., CANbridge Pharmaceuticals Inc., Kira Pharmaceuticals LLC, and a Partner at Qiming Venture Partners Ltd.
Dr. Chen previously worked as a Director at Abbisko Therapeutics Co., Ltd., Jiangsu Yahong Meditech Co., Ltd., and Abbisko Cayman Ltd.
Dr. Chen also served as a Non-Executive Director at Antengene Corporation Co., Ltd.
and Antengene Corp.
Ltd.
Dr. Chen received a doctorate degree from Case Western Reserve University in 2009 and an undergraduate degree from Fudan University in 2004.
Postes actifs de Kan Chen
| Sociétés | Poste | Début |
|---|---|---|
| CONNECT BIOPHARMA HOLDINGS LIMITED | Directeur/Membre du Conseil | 01/12/2020 |
| CANBRIDGE PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 16/12/2020 |
| Kira Pharmaceuticals LLC | Directeur/Membre du Conseil | 01/04/2020 |
Insilico Medicine Cayman TopCo
 Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | Directeur/Membre du Conseil | 01/08/2021 |
InSilico Medicine, Inc.
 InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | Directeur/Membre du Conseil | - |
InSilico Medicine Hong Kong Ltd.
 InSilico Medicine Hong Kong Ltd. Information Technology ServicesTechnology Services InSilico Medicine Hong Kong Ltd. operates as bioinformatics company, which utilizes advances in genomics, big data analysis and deep learning for silico drug discovery and drug repurposing for aging and age-related diseases. The company was founded by Alex Zhavoronkov and is headquartered in Hong Kong. | Directeur/Membre du Conseil | - |
Suzhou Connect Biopharma Co. Ltd.
 Suzhou Connect Biopharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China. | Directeur/Membre du Conseil | - |
Qiming Venture Partners Ltd.
 Qiming Venture Partners Ltd. Investment ManagersFinance Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China. | Private Equity Investor | 01/02/2016 |
CANbridge Life Sciences Ltd.
 CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China. | Directeur/Membre du Conseil | - |
| ░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Kan Chen
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░ ░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Kan Chen
| Fudan University | Undergraduate Degree |
| Case Western Reserve University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| CONNECT BIOPHARMA HOLDINGS LIMITED | Health Technology |
| JIANGSU YAHONG MEDITECH CO., LTD. | Health Technology |
| CANBRIDGE PHARMACEUTICALS INC. | Health Technology |
| ANTENGENE CORPORATION LIMITED | Health Technology |
| ABBISKO CAYMAN LIMITED | Health Technology |
| Entreprise privées | 10 |
|---|---|
Zion Pharma Ltd.
 Zion Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm). | Commercial Services |
Abbisko Therapeutics Co., Ltd.
 Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Abbisko Therapeutics Co., Ltd. engages in the research and development of biomedicine and biotechnology. Its business includes technology transfer, technical advisory, and technical services. The company was founded on April 12, 2016 and is headquartered in Shanghai, China. | Health Technology |
CANbridge Life Sciences Ltd.
CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China. | Health Technology |
Qiming Venture Partners Ltd.
Qiming Venture Partners Ltd. Investment ManagersFinance Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China. | Finance |
| Kira Pharmaceuticals LLC | |
Suzhou Connect Biopharma Co. Ltd.
Suzhou Connect Biopharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China. | Health Technology |
InSilico Medicine Hong Kong Ltd.
InSilico Medicine Hong Kong Ltd. Information Technology ServicesTechnology Services InSilico Medicine Hong Kong Ltd. operates as bioinformatics company, which utilizes advances in genomics, big data analysis and deep learning for silico drug discovery and drug repurposing for aging and age-related diseases. The company was founded by Alex Zhavoronkov and is headquartered in Hong Kong. | Technology Services |
Antengene Corporation Co., Ltd.
 Antengene Corporation Co., Ltd. Pharmaceuticals: MajorHealth Technology Antengene Corporation Co., Ltd. operates as a holding company. It engages in clinical development of drug candidates. The company was founded on June 15, 2016 and is headquartered in Shanghai, China. | Health Technology |
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | Technology Services |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | Commercial Services |
